Jonathan Pachter

Company: Verastem. inc
Job title: CSO
Seminars:
Tumor/Biomarker-Specific Combination Strategies with the RAF/MEK Clamp VS-6766 4:30 pm
VS-6766 blocks the RAS pathway through a novel RAF/MEK clamp mechanism Rationale for ongoing combination trials with VS-6766 with defactinib or everolimus Novel VS-6766 combinations for tumor/biomarkerspecific patient populationsRead more
day: Day One Track H